vi

LIST OF TABLES
There are a few explanations for why osteoporosis is known to affect breast cancer survivors at higher rates than women who have not had breast cancer. Chemotherapy and radiation are known to damage bone formation cells. Hormonal therapies to treat breast cancer often decrease estrogen levels, which adversely affect bone health. Women may also reach menopause earlier due to breast cancer treatments. All of the above factors result in a higher occurrence of osteoporosis for breast cancer survivors. Finally, women who survive breast cancer may have a long life expectancy and therefore could be impacted by osteoporosis, a disease that affects mobility and quality of life. The goal of this study was to determine if vitamin D insufficiency was a problem for women who have survived breast cancer and therefore remain at high risk for osteoporosis compared to postmenopausal women with no history of breast cancer.
Chapter 2: Literature Review
Vitamin D deficiency was thought to be a problem of the past in the United States. Humans and other mammals can produce vitamin D when exposed to ultraviolet blue (UVB) light, typically provided by sunlight. In addition, fortification of cow's milk and supplementation of vitamin D through multivitamins and calcium tablets is common. However, recent studies have documented a surprisingly high prevalence of deficiency across all age groups worldwide, particularly in infants, 1 the elderly, 2 persons of color, 3 and those residing at higher latitudes. 4 
Vitamin D and Incidence of Disease
Recent epidemiological data have shown that inadequate vitamin D status is correlated with diseases other than rickets, osteomalacia, and osteoporosis. The discovery of vitamin D receptors (VDR) in more than 30 body tissues has provided data as to how vitamin D may play a role in the development of a number of conditions, including cancer. 5 Epidemiological evidence has shown a correlation between higher levels of sunlight exposure and decreased mortality from breast, colon, and prostate cancers. The geographical patterns of mortality from these types of cancer are similar to the occurrence of rickets, a disease of vitamin D deficiency. study of more than 150,000 women investigated differences in breast cancer incidence and found that African Americans are disproportionately at risk for breast cancer mortality. 13 Grann et al. 14 analyzed epidemiological data and also noted that mortality from breast cancer was higher in African 
Bone Health, Vitamin D, and Breast Cancer Survivors
Women who have received treatment for breast cancer are acutely at risk for osteoporosis for several reasons. Osteoporosis has been shown to be a common disease in postmenopausal women, with one in 3 women over the age of 50 worldwide being affected with this condition.
Estrogen is a key factor in bone turnover, and the reduction in estrogen concentrations after menopause has been shown to cause the rate of bone loss to increase by two-to four-fold. Women who reach menopause earlier due to ovarian failure induced by chemotherapy may be especially at risk for developing osteoporosis due to a longer post-menopausal lifespan. 39 In addition, since 60-70% of breast cancers in postmenopausal women are hormone-receptor positive, they are often treated by estrogen deprivation. Toxic effects of chemotherapy have also been shown to damage bone formation cells. 39.40 Vitamin D is critical in the protection of bone health, and an insufficient concentration of vitamin D is known to increase the risk of fracture and osteoporosis. 41 Breast cancer survivors have been shown to have significantly lower bone mineral density than controls after adjusting for age, race, and years since menopause. 40 Assessment of vitamin D status in breast cancer survivors could provide data to better manage the risk of osteoporosis in this population.
Chapter 3: Research Design and Methodology
This study was designed to document the prevalence of vitamin D insufficiency in breast cancer survivors (BCS) and compare these rates to those found in healthy female controls.
Subjects
Ninety-eight BCS who had completed their treatment at least 6 months before initiation of the present study and 55 control subjects were recruited for the present study. The BCS who participated in the present study were women with no active cancer growth after completion of their chemotherapy or radiation treatments and who returned for follow-up analysis at the Cancer Treatment Centers of America (CTCA) at Midwestern Regional Medical Center (MRMC), Zion, IL.
Controls were age and menopausal matched healthy female volunteers who were employees of the CTCA.
Prior to taking part in the study, all participants had to provide informed consent (Appendix C). Eighty-three percent of participants in both groups were Caucasian. Ethnic distribution was different between the two groups, with slightly more Asians in the control group and slightly more African Americans in the BCS group (Table 1) . There was no significant difference in age or body mass index (BMI) between the two groups. The majority (80%) of the BCS had been diagnosed with stage one or stage two breast cancers (Table 2) . Seventy-two percent of the BCS had estrogen-receptor positive (ER+) tumors, 60% had progesterone-receptor positive (PR+) tumors, and 80% had HER2/neu negative tumors. Most of the BCS had received surgery followed by chemotherapy or radiation as their treatment for cancer.
One subject had undergone a stem cell transplant. A majority of the BCS (73%) were not taking hormonal therapy for breast cancer at the time of the study ( Table 2) . Persons with the following medical conditions were excluded from the study: undergoing current dialysis treatment, elevated liver enzymes, primary hyperparathyroidism, hypercalcemia, hypercalciuria, or Paget's disease.
The MRMC Institutional Review Board and the Eastern Michigan University Human Subjects
Committee approved this study (Appendices D, E.)
Research Design
The present research project was an observational, case-controlled study that was conducted over a twelve-month period. Subjects were recruited from a group of BCS who had scheduled follow-up appointments at MRMC in 2007. These potential subjects were mailed an invitation to participate in the study prior to their appointment. Control women were employees of MRMC and were recruited using a public email invitation. All participants provided a blood sample at MRMC that was tested for 25-hydroxy vitamin D. They also completed a food frequency questionnaire that included a list of current vitamin and mineral supplements and their consumption rate and also provided their present zip code of residence.
Biochemical Analysis
All 
Survey Instrument
All participants were surveyed when they visited MRMC to obtain demographic information and medical history. The principal investigator (a registered dietitian) met with each participant to review and collect all surveys upon completion and to answer any questions regarding the study and the survey.
Demographic information collected included each subject's age, sex, race, height, weight, and zip code of residence. Medical histories included non-cancer-related medical information; type, stage, and date of breast cancer diagnosis; completed cancer treatment regimens, and current medications (Appendix A). Medical records were used to obtain pertinent health and cancer treatment related information when subjects could not answer relevant questions.
Sunlight Exposure Calculations
Amount of exposure to ultraviolet blue (UVB) radiation was approximated for each participant based on latitude of residence. Zip codes of residence were used to determine the latitudes of residence. Zip code information was obtained in the demographic questionnaire (Appendix A). No data were collected regarding sunscreen use or time spent outdoors.
Food Frequency Questionnaire
Dietary intake of vitamin D was determined using data from a modified food frequency questionnaire originally developed by Blalock et al. 42 (Appendix B). This questionnaire provided data regarding calcium and vitamin D intake as well as intake of other vitamins, minerals, and herbal supplements.
Statistical Analysis
Participants 
Dietary Vitamin D Intake
The majority of BCS and controls did not consume adequate amounts of dietary vitamin D.
The dietary reference intake (DRI) for vitamin D is 400 IU daily. Average daily intake of vitamin D among BCS was 140 IU/day; whereas among controls it was 135 IU/day. Only 9 subjects met the DRI for vitamin D solely with food intake (8 BCS, 1 control). Eight of these women consumed fatty fish regularly (about one serving/day). One woman consumed 72 oz. of whole milk daily.
Supplemental Vitamin D Intake
Supplement intake varied widely and explained only 31% of the variation in serum 25 Finally, both groups were asked about their current bone health in the medical questionnaire.
Breast cancer survivors had a significantly higher burden of bone disease (osteopenia or osteoporosis) than controls (32% vs. 13%) (P<0.0331).
Chapter 5: Discussion
Finding a majority of participants to be deficient in vitamin D was not surprising, considering the epidemic of vitamin D deficiency in the general population. 43 The finding of exceptionally high rates of vitamin D deficiency were consistent with other results reported in research studies that compared healthy women and BCS. 27, 28, 38 Tangpricha et al. 3 found that 20-30%
of their cohort were deficient in vitamin D when ≤20ng/dL was used as a cutoff for deficiency.
Kakarala et al. 44 Supplemental intake of vitamin D was one area where significant differences were found between BCS and controls. BCS had significantly higher levels of vitamin D intake from supplements (1013 IU vs. 421 IU). Studies suggest that persons who have survived cancer are more likely to take vitamin or mineral supplements than persons who have no history of cancer. 48 A more recent survey of cancer survivors found that 73% took supplements of some type. Caucasian women were most likely to take supplements compared to other races and to men. Vitamin D supplements are also one of the most commonly taken nutritional supplements. 49 In addition, CTCA It may have been expected to see differences in 25(OH)D concentrations between ethnic groups due to differences in skin melanin levels, but no variability was seen. This is most likely due to the extremely low concentrations of vitamin D of all participants and the probable lack of sunlight exposure among all participants. The study population was also mostly Caucasian, which may not have permitted an adequate sample size of any other ethnic group to see differences.
The findings of significantly more bone disease in BCS is not remarkable, as it is known that decreases in estrogen due to cancer therapies that promote earlier menopause as well as that chemotherapy and radiation negatively impact bone health. It is known that vitamin D is critical in maintaining adequate calcium stores. 26 This highlights an important opportunity for clinicians to protect bone health by assessing vitamin D status and correcting deficiencies in BCS.
Overall, the majority of both populations were deficient in vitamin D. A predictor of adequate vitamin D status in this study was vitamin D supplement intake >2000 IU daily. All data collected in this study will be kept confidential and no patient identifiers will ever be used in reportable analysis.
APPENDICES
ARE THERE BENEFITS TO TAKING PART IN THE STUDY?
If you agree to take part in this study, there may or may not be direct medical benefit to you. We hope the information learned from this study will benefit other patients with cancer in the future. A complimentary 30 minute appointment with a registered dietitian will be offered to participants. Those persons found to be deficient in vitamin D will be counseled on appropriate actions to resolve deficiency as a normal part of counseling by the nutrition department at MRMC.
WHAT ABOUT CONFIDENTIALITY? AUTHORIZATION TO USE AND DISCLOSE MEDICAL INFORMATION
Section 1 Introduction
This form is provided to you because you have agreed to participate in a clinical research study. You have received a separate informed consent form describing the study and seeking your consent to take part.
In the course of the study, medical information will be created about each person who takes part. This form will explain how your medical information will be used and who may see it. If you wish to allow your medical information to be collected, used and shared with certain persons involved in the study, you will be asked to sign this form. If you do not sign this form, you will not be able to take part in the study.
Read this information carefully and please ask the study doctor or the study staff if you have any questions.
Section 2 Authorization to Collect, Use and Disclose Your Medical Information
The following sections explain how your medical information will be collected, used and shared with certain other persons involved in the study and describe your rights, including your right to see your medical information.
Section 3 Purpose of This Authorization
You are being asked to permit the collection, use and sharing of your medical information so that the safety and effectiveness of the study drug can be evaluated as described in the informed consent form.
Section 4 What Does Medical Information Mean?
Your medical information is information about your physical or mental health or condition. It includes your previous medical records and information about you created or collected during the study (for example, the dates or results of various tests or examinations). This information may identify you because it may contain, for example, your name, address, telephone number, photograph, date of birth, social security number, race or ethnic origin or other unique identifiers.
Section 5 Use and Disclosure of Your Medical Information
If you sign this form, you allow the study doctor to collect and use your medical information to carry out this study. You also allow the study doctor to share your medical information with:
other doctors and health care professionals who are involved in the study;
the Institutional Review Board (IRB) that watches over the study; and government agencies overseeing this study or the study drug, including the Food and Drug Administration (FDA), other Department of Health and Human Services agencies, and government agencies in the United States and other countries.
Section 6 Will Persons Looking At Your Medical Information Be Able to Identify You?
That part of your medical information sent by the study doctor to the other institutions listed above ("study data") usually does not identify you personally (for example, by name, address, or social security number. However, an example of data that may be sent to another institution is your date of birth). Instead, the study doctor uses your initials and a code number on the study data sent to other institutions. However, authorized personnel from the FDA, other Department of Health and Human Services agencies, government agencies in other countries, the Institutional Review Board and other supervising bodies may look at all your medical information at the study doctor's site. The reason these persons may look at your medical information is to make sure the study has been done properly and that study data has been collected correctly, or for other reasons allowed by law.
Section 7 Notice on Redisclosure of Your Medical information and Confidentiality
Federal law provides that the study doctor can only share your medical information with those persons whom you have permitted to see it. However, if you sign this form, those persons may share your medical information with other persons. Federal law does not protect you against this. (The laws of your state may provide additional privacy protection.)
Section 8 Publication of Study Results
Except as explained in this form, your medical information will be kept confidential. The data and results from this study may also be presented at meetings or in publications, but in those presentations people taking part in the study will not be identified by name.
Section 9 Your Right to See and/or Copy Your Medical Information
You have the right to see and copy your medical information related to the study for as long as the study doctor holds this information. However, you may not be able to see some of your records related to the study until after the study has been completed, otherwise it could spoil the study.
Section 10 Withdrawing Your Authorization
You may withdraw your Authorization (permission) regarding your medical information at any time by writing to the study doctor at the following address: 2520 Elisha Avenue, Zion, IL 60099. If you Taking part in this survey is voluntary. You may choose not to take part or may leave the study at any time. Leaving the study will not result in any penalty or loss of benefits to which you are entitled.
You are free to withdraw your consent to participate in this study at any time without prejudice to your subsequent care.
We will tell you about new information that may affect your health, welfare, or willingness to stay in this study.
WHOM DO YOU CALL IF YOU HAVE QUESTIONS OR PROBLEMS?
For questions about your rights as a research participant, contact Dr. Harlan Verrill , Chairman of the Institutional Review Board of Research and Ethics at Midwestern Regional Medical Center (which is a group of people who review the research to protect your rights) at 847-872-6147.
You will get a copy of this form. You may also request a copy of the protocol (full study plan).
Signatures
You have read all of the above, asked questions, received answers concerning areas you did not understand, and willingly give your consent to participate in this program. Upon signing this form you will receive a copy. 
